Triple threat: drug cocktail and precision radiation take on tough bile duct cancer
NCT ID NCT07635290
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a combination of two drugs (anlotinib and cadonilimab) plus a special type of radiation (PULSAR) in 26 people with advanced bile duct cancer that has worsened after standard treatment. The goal is to see if this triple therapy can shrink tumors and control the disease, while monitoring side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anlotinib, Cadonilimab, and PULSAR radiation
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced biliary tract cancer who have run out of standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 26 participants, so results may not apply to everyone. The combination may cause significant side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UNRESECTABLE OR METASTATIC BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.